Comparative Pharmacology
Head-to-head clinical analysis: ANGIOMAX versus HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOMAX versus HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
ANGIOMAX vs HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, blocking its interaction with substrates, thereby inhibiting fibrin formation and activation of coagulation factors V, VIII, and XIII.
Heparin binds to antithrombin III, accelerating its inhibition of thrombin (factor IIa) and factor Xa, thereby preventing fibrin clot formation.
1 mg/kg intravenous bolus followed by 0.1 mg/kg/hour continuous intravenous infusion for duration of procedure; alternatively, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg/hour continuous intravenous infusion for up to 4 hours during percutaneous coronary intervention.
Initial IV bolus of 80 units/kg, followed by continuous IV infusion at 18 units/kg/hour; subsequent dosing based on aPTT. For DVT/PE: initial bolus of 5,000 units or 80 units/kg, then 1,000-2,000 units/hour continuously.
None Documented
None Documented
Terminal elimination half-life: 25-30 minutes in patients with normal renal function; increased to 2-3 hours in dialysis-dependent patients
30–90 minutes (mean 1.5 h) for therapeutic doses; dose-dependent and saturable elimination: increases with dose (e.g., 100 U/kg: ~56 min; 400 U/kg: ~152 min). At lower doses, half-life may be shorter due to rapid clearance.
Renal: ~90% unchanged; biliary/fecal: negligible (<1%)
Renal: minimal intact heparin; primarily hepatic degradation via desulfation and depolymerization into inactive metabolites (uroheparin) excreted renally. Biliary/fecal: negligible (<1%).
Category C
Category A/B
Anticoagulant
Anticoagulant